Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2026 | $22.00 | Buy | Stifel |
| 4/20/2026 | Overweight | Cantor Fitzgerald | |
| 10/28/2025 | $15.00 | Overweight | Stephens |
| 9/3/2025 | $7.00 | Buy → Neutral | BofA Securities |
| 6/30/2025 | $23.00 | Buy | H.C. Wainwright |
| 2/20/2025 | $25.00 | Buy | Citigroup |
| 2/19/2025 | $20.00 | Buy | Canaccord Genuity |
| 2/7/2025 | $15.00 | Buy | BofA Securities |
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
3 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 6, 2026, the Compensation Committee of Candel’s Board of Directors granted Mark Sims, in connection with his employment as the Chief Commercial Officer of Candel, stock options to purchase an aggregate of 285,000 shares of the Company’s common stock, with a per share exercise price of $10.03, which is equal to the closing price of the Company’s common stock on The Nasdaq Global Market on July 6, 2026. Th
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on June 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 25,000 shares of the Company’s common stock, with a per share exercise price of $10.30. The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying th
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior pembrolizumab and platinum chemotherapyGlobal pivotal phase 3 trial expected to enroll patients in 1:1 randomization across more than 150 sites; first site now open for enrollmentPrimary endpoint is overall survivalCandel has engaged Parexel International to support execution of this global pivotal trial NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NA
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
Stifel initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $22.00
Cantor Fitzgerald initiated coverage of Candel Therapeutics with a rating of Overweight
Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00
Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Mark Sims as the Company’s Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) in interm
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)
SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration compared to placebo, reinforcing the potential of aglatimagene to reduce the risk of tumor recurrence in men receiving radiotherapy for localized disease.Clinical benefit demonstrated in the intention-to treat (ITT) population by secondary and clinically relevant exploratory endpoints with numerical improvements observed in time to biochemical failure (TTBF), lower incidence of and increased time to metastase
Conference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Candel's management will host a webcast and conference call on Friday, May 15, 2026 at 1:00 PM ET. The call will discuss the Company's extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer. The discussion will follow the oral plena
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr.